返回 Agenda
Parallel Session 6B: Clinical Trials
Session Chair(s)
Angelika Joos, MPHARM
Executive Director, Science & Regulatory Policy, MSD, Belgium
This session will discuss the evolution of the continental clinical trials landscape in Africa through AVAREF, provide insights into the revised ICH E6(R3) guidelines that is going to be adopted by end of 2024 and Clinical research opportunities in the Kingdom of Saudi Arabia. We will also host a panel discussion to hear more how the clinical trial frameworks are evolving in Egypt and Bahrain as well as some reflections from the pharmaceutical Industry.
Speaker(s)
Rhanda Adechina Adehan
Technical Officer - Consultant AVAREF Secretariat, World Health Organization (WHO), Switzerland
Continental Clinical Trials
Rebecca Stanbrook, RPH
EFPIA ICH E6(R3) Expert Working Group Member, RESaltas GmbH, Switzerland
ICH E6/E8 revision update
Halah Alenizi
Clinical Trials Expert, Saudi National Institute of Health (Saudi NIH), Saudi Arabia
The Experience from Saudi NIH
Abdulhadi M. Alqahtani
Sr. Clinical Trial Specialist, Saudi National Institute of Health (Saudi NIH), Saudi Arabia
The Experience from Saudi NIH
Heba Khalil
Head of GA of Clinical Trials, Egyptian Drug Authority (EDA), Egypt
Panel Discussion with QandA, with the additional participation of
Sumaya Husain
Clinical Trials Regulations Specialist, National Health Regulatory Authority (NHRA), Bahrain
Panel Discussion with QandA, with the additional participation of
Mohei-Eldeen Hesham
Evidence Generation Manager, AbbVie, Saudi Arabia
Panel Discussion with QandA, with the additional participation of